Clinical Trial

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Study acronym: SLIDE-HCC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-03-11; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT06880523
Lead Sponsor Canadian Cancer Trials Group
Collaborators: AstraZeneca, National Cancer Institute, Naples
Conditions Hepatocellular Carcinoma
Enrollment 140 participants
Start Date 2025-10-21
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11